Zhang Manka, Ma Huimin, Zhang Jian, He Lingling, Ye Xiaohui, Li Xin
Department of Center of Integrated Traditional Chinese and Western Medicine, Peking University Ditan Teaching Hospital.
Department of Center of Integrated Traditional Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University.
Onco Targets Ther. 2017 Oct 3;10:4829-4839. doi: 10.2147/OTT.S141968. eCollection 2017.
Hepatic resection (HRN) and microwave ablation (MWA) have significant advantages in treating hepatocellular carcinoma; however, it remains unclear which way produces better outcomes. This meta-analysis of cohort studies compared the treatments in terms of effectiveness and safety.
Six electronic databases (PubMed, Medline, EMBASE, Web of Science, EBSCO, and The Cochrane Library) were retrieved for studies comparing MWA and HRN. The meta-analysis was conducted based on statement of preferred reporting items for systematic reviews and meta-analyses.
Nine studies met the inclusion criteria, with a total of 1,480 patients. The overall meta-analysis demonstrated no significant difference in overall survival between the MWA group and the HRN group (HR =0.98, 95% CI =0.76-1.26, =0.878). There was no difference in disease-free survival between the MWA group and the HRN group (HR =1.16, 95% CI =0.79-1.71, =0.442). Meanwhile, the meta-analysis demonstrated that MWA was associated with shorter operation time (standardized mean difference [SMD] =-1.37, 95% CI =-1.92 to -0.81, =0.000), less amount of blood loss in operation (SWD =-1.19, 95% CI =-1.76 to -0.61, =0.000), and less complications (OR =0.22, 95% CI =0.12-0.40, =0.000) than HRN.
In conclusion, our meta-analysis suggests that MWA may be superior to HRN as it is as effective as HRN in terms of overall survival, disease-free survival, tumor recurrence, and is associated with shorter operation time, less amount of blood loss, and fewer complications.
肝切除术(HRN)和微波消融术(MWA)在治疗肝细胞癌方面具有显著优势;然而,哪种方法能产生更好的效果仍不清楚。这项队列研究的荟萃分析从有效性和安全性方面比较了这两种治疗方法。
检索了六个电子数据库(PubMed、Medline、EMBASE、Web of Science、EBSCO和Cochrane图书馆)以查找比较MWA和HRN的研究。荟萃分析是根据系统评价和荟萃分析的首选报告项目声明进行的。
九项研究符合纳入标准,共有1480例患者。总体荟萃分析表明,MWA组和HRN组的总生存期无显著差异(风险比[HR]=0.98,95%置信区间[CI]=0.76-1.26,P=0.878)。MWA组和HRN组的无病生存期无差异(HR=1.16,95%CI=0.79-1.71,P=0.442)。同时,荟萃分析表明,与HRN相比,MWA的手术时间更短(标准化均数差[SMD]=-1.37,95%CI=-1.92至-0.81,P=0.000),术中失血量更少(SMD=-1.19,95%CI=-1.76至-0.61,P=0.000),并发症更少(比值比[OR]=0.22,95%CI=0.12-0.40,P=0.000)。
总之,我们的荟萃分析表明,MWA可能优于HRN,因为它在总生存期、无病生存期、肿瘤复发方面与HRN一样有效,并且手术时间更短,失血量更少,并发症更少。